This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Healthcare Companies: RegenXBio (RGNX), Align Tech (ALGN) and Keros Therapeutics (KROS)

Tipranks - Tipranks - Sat May 16, 6:20AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on RegenXBio (RGNX), Align Tech (ALGN) and Keros Therapeutics (KROS).

Claim 55% Off TipRanks

RegenXBio (RGNX)

Goldman Sachs analyst Paul Choi maintained a Hold rating on RegenXBio today and set a price target of $10.00. The company’s shares closed last Thursday at $6.25, close to its 52-week low of $5.62.

According to TipRanks.com, Choi is a 4-star analyst with an average return of 8.8% and a 55.0% success rate. Choi covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Arvinas Holding Company, and Corvus Pharmaceuticals. ;'>

Currently, the analyst consensus on RegenXBio is a Strong Buy with an average price target of $23.63, a 192.5% upside from current levels. In a report released yesterday, TipRanks – Google also upgraded the stock to Hold with a $10.50 price target.

See Insiders’ Hot Stocks on TipRanks >>

Align Tech (ALGN)

In a report released today, Jason Bednar from Piper Sandler reiterated a Buy rating on Align Tech, with a price target of $235.00. The company’s shares closed last Thursday at $160.53, close to its 52-week low of $157.57.

According to TipRanks.com, Bednar is ranked 0 out of 5 stars with an average return of -5.8% and a 38.2% success rate. Bednar covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Merit Medical Systems, and Solventum Corporation. ;'>

Currently, the analyst consensus on Align Tech is a Moderate Buy with an average price target of $203.27, which is a 25.9% upside from current levels. In a report issued on April 30, TipRanks – PerPlexity also upgraded the stock to Buy with a $200.00 price target.

Keros Therapeutics (KROS)

Wells Fargo analyst Benjamin Burnett maintained a Buy rating on Keros Therapeutics today and set a price target of $20.00. The company’s shares closed last Thursday at $10.99, close to its 52-week low of $9.78.

According to TipRanks.com, Burnett is a 1-star analyst with an average return of -1.2% and a 42.5% success rate. Burnett covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Rapport Therapeutics, Inc., and Ultragenyx Pharmaceutical. ;'>

Keros Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $21.20, which is an 80.6% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.

Read More on RGNX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).